SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).
José Alejandro Pérez-FidalgoFernando Gálvez-MontosaEva María GuerraAinhoa MadariagaAranzazu ManzanoCristina Martin-LorenteMaria Jesús Rubio-PérezJesus AlarcónMaría Pilar Barretina-GinestaLydia GabaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.